Search by Drug Name or NDC
NDC 00006-3026-02 KEYTRUDA 25 mg/mL Details
KEYTRUDA 25 mg/mL
KEYTRUDA is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is PEMBROLIZUMAB.
MedlinePlus Drug Summary
Pembrolizumab injection is used alone or in combination with other chemotherapy medications to treat certain types of melanoma (a type of skin cancer), Merkel cell carcinoma (MCC; a type of skin cancer), and cutaneous squamous cell carcinoma (CSCC; skin cancer). It is also used to prevent the return of melanoma after surgery. Pembrolizumab injection is also used alone and/or in combination with other chemotherapy medications to treat certain types of lung cancer (non-small-cell lung cancer; NSCLC), head and neck cancer, Hodgkin's lymphoma (Hodgkin's disease), primary mediastinal B-cell lymphoma (PMBCL; non-Hodgkin lymphoma), urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract), bladder cancer, colorectal cancer (cancer that begins in the large intestine), gastric cancer (cancer of the stomach), esophageal cancer (cancer of the tube that connects your throat to your stomach), cervical cancer (cancer that begins in the opening of the uterus [womb]), cancer of the endometrium (lining of the uterus), hepatocellular carcinoma (HCC; a type of liver cancer), renal cell carcinoma (RCC, a type of cancer that begins in the kidneys), breast cancer, and certain other solid tumors. Pembrolizumab injection is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells. Your doctor will review your specific type of cancer and past treatment history and other available treatments to determine if pembrolizumab is right for you.
Related Packages: 00006-3026-02Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Pembrolizumab Injection
Product Information
NDC | 00006-3026 |
---|---|
Product ID | 0006-3026_1780018b-86df-4a41-bf1c-2ea84d23621c |
Associated GPIs | 21357953002030 |
GCN Sequence Number | 073360 |
GCN Sequence Number Description | pembrolizumab VIAL 100 MG/4ML INTRAVEN |
HIC3 | V3R |
HIC3 Description | ANTINEOPLASTIC,ANTI-PROGRAMMED DEATH-1 (PD-1) MAB |
GCN | 37754 |
HICL Sequence Number | 041369 |
HICL Sequence Number Description | PEMBROLIZUMAB |
Brand/Generic | Brand |
Proprietary Name | KEYTRUDA |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | pembrolizumab |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 25 |
Active Ingredient Units | mg/mL |
Substance Name | PEMBROLIZUMAB |
Labeler Name | Merck Sharp & Dohme LLC |
Pharmaceutical Class | Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA125514 |
Listing Certified Through | 2025-12-31 |
Package
NDC 00006-3026-02 (00006302602)
NDC Package Code | 0006-3026-02 |
---|---|
Billing NDC | 00006302602 |
Package | 1 VIAL in 1 CARTON (0006-3026-02) / 4 mL in 1 VIAL (0006-3026-01) |
Marketing Start Date | 2015-01-15 |
NDC Exclude Flag | N |
Pricing Information | N/A |